Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Efficacy and Safety of a New Premature Infant Formula 1514

Objective: This prospective, parallel, randomized, double-blind, multicenter study compared growth, safety, and tolerance in preterm infants fed a new (E1) or standard (E2) 24 kcal/oz LBW infant formula. This was an outpatient continuation (Phase II) of an inpatient study (Phase I). Phase I was enrollment to hospital discharge at 36 weeks, and Phase II from hospital discharge to 40 weeks postconceptional age (PCA).

Methods: At enrollment, preterm infants were stratified into subgroups according to PCA (25-28 weeks; 29-31 weeks; 32-34 weeks) and then randomly assigned to 1 of 2 study formulas which were identical except for higher protein (22 g vs 20 g/L) and vitamin and mineral levels (1000 vs 800 mg Ca/L; 600 vs 425 mg P/L) in E1. Daily weights (Wt), weekly measurements of length (Lt) and head circumference (OFC) were obtained during Phase I, at hospital discharge, and at the end of Phase II. Serum chemistries were drawn at enrollment, biweekly during Phase I, at hospital discharge, and at the end of Phase II. Adverse events were monitored during the study.

Results: 106/133 infants completed Phase I, and 89 completed Phase II, Wt, Lt, OFC, formula intake, serum chemistries and the incidence of adverse events such as bradycardia, apnea, and anemia were similar in both formula groups.

Conclusion: The new E1 formula with higher protein, vitamin and mineral levels is safe, well tolerated, and supports nutrient absorption and retention comparable to a standard LBW formula (E2). Table

Table 1 No caption available.

Author information



Additional information

Study sponsored by Wyeth Nutritionals International.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Fessard, C., Rose, S., Putet, G. et al. Efficacy and Safety of a New Premature Infant Formula 1514. Pediatr Res 43, 259 (1998).

Download citation


Quick links